Ground shifts in pharma

A RM281.67mil contract to produce human insulin is shifting the momentum in Malaysia’s pharmaceutical sector and reinforcing the government’s push for stronger local manufacturing.

For Pharmaniaga Bhd, the three-year contract to supply human insulin to government hospitals comes at a pivotal moment, just weeks after its formal exit from the Practice Note 17 (PN17) status.